Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Thomas Graillon
,
Marc Sanson
,
Chantal Campello
,
Ahmed Idbaih
,
Matthieu Peyre
,
Hadrien Peyrière
,
Noémie Basset
,
Didier Autran
,
Michel Kalamarides
,
Pierre-Hugues Roche
,
Stéphane Fuentes
,
Emeline Tabouret
(1)
,
Maryline Barrie
,
Anita Cohen
,
Stéphane Honoré
(1)
,
Mohamed Boucekine
,
Karine Baumstarck
,
Dominique Figarella‑branger
(1)
,
Anne A. Barlier
,
Henry Dufour
,
Olivier Louis Chinot
(1)
Thomas Graillon
- Function : Author
- PersonId : 16770
- IdHAL : thomas-graillon
- ORCID : 0000-0001-5627-8181
- IdRef : 161600131
Marc Sanson
- Function : Author
- PersonId : 760119
- ORCID : 0000-0002-1813-8476
Chantal Campello
- Function : Author
Ahmed Idbaih
- Function : Author
- PersonId : 760123
- ORCID : 0000-0001-5290-1204
- IdRef : 114953139
Matthieu Peyre
- Function : Author
Hadrien Peyrière
- Function : Author
Noémie Basset
- Function : Author
Didier Autran
- Function : Author
Michel Kalamarides
- Function : Author
- PersonId : 767013
- ORCID : 0000-0003-1037-9707
Pierre-Hugues Roche
- Function : Author
Stéphane Fuentes
- Function : Author
Emeline Tabouret
- Function : Author
- PersonId : 172013
- IdHAL : emeline-tabouret
- ORCID : 0000-0002-4031-2178
- IdRef : 184235065
Maryline Barrie
- Function : Author
Anita Cohen
- Function : Author
Stéphane Honoré
- Function : Author
- PersonId : 174961
- IdHAL : stephane-honore
Mohamed Boucekine
- Function : Author
Karine Baumstarck
- Function : Author
Dominique Figarella‑branger
- Function : Author
- PersonId : 18293
- IdHAL : dominique-figarella-branger
- ORCID : 0000-0002-3604-887X
- IdRef : 067213642
Anne A. Barlier
- Function : Author
- PersonId : 16684
- IdHAL : anne-barlier
- ORCID : 0000-0002-3740-6173
- IdRef : 143313339
Henry Dufour
- Function : Author
Abstract
Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.